1
|
Sobhani-Nasab A, Banafshe HR, Atapour A, Khaksary Mahabady M, Akbari M, Daraei A, Mansoori Y, Moradi Hasan-Abad A. The use of nanoparticles in the treatment of infectious diseases and cancer, dental applications and tissue regeneration: a review. Front Med Technol 2024; 5:1330007. [PMID: 38323112 PMCID: PMC10844477 DOI: 10.3389/fmedt.2023.1330007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 12/12/2023] [Indexed: 02/08/2024] Open
Abstract
The emergence of nanotechnology as a field of study can be traced back to the 1980s, at which point the means to artificially produce, control, and observe matter on a nanometer level was made viable. Recent advancements in technology have enabled us to extend our reach to the nanoscale, which has presented an unparalleled opportunity to directly target biomolecular interactions. As a result of these developments, there is a drive to arise intelligent nanostructures capable of overcoming the obstacles that have impeded the progress of conventional pharmacological methodologies. After four decades, the gradual amalgamation of bio- and nanotechnologies is initiating a revolution in the realm of disease detection, treatment, and monitoring, as well as unsolved medical predicaments. Although a significant portion of research in the field is still confined to laboratories, the initial application of nanotechnology as treatments, vaccines, pharmaceuticals, and diagnostic equipment has now obtained endorsement for commercialization and clinical practice. The current issue presents an overview of the latest progress in nanomedical strategies towards alleviating antibiotic resistance, diagnosing and treating cancer, addressing neurodegenerative disorders, and an array of applications, encompassing dentistry and tuberculosis treatment. The current investigation also scrutinizes the deployment of sophisticated smart nanostructured materials in fields of application such as regenerative medicine, as well as the management of targeted and sustained release of pharmaceuticals and therapeutic interventions. The aforementioned concept exhibits the potential for revolutionary advancements within the field of immunotherapy, as it introduces the utilization of implanted vaccine technology to consistently regulate and augment immune functions. Concurrently with the endeavor to attain the advantages of nanomedical intervention, it is essential to enhance the unceasing emphasis on nanotoxicological research and the regulation of nanomedications' safety. This initiative is crucial in achieving the advancement in medicine that currently lies within our reach.
Collapse
Affiliation(s)
- Ali Sobhani-Nasab
- Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
| | - Hamid Reza Banafshe
- Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
| | - Amir Atapour
- Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mahmood Khaksary Mahabady
- Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
| | - Maryam Akbari
- Department of Surgery, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
| | - Abdolreza Daraei
- Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
| | - Yaser Mansoori
- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
| | - Amin Moradi Hasan-Abad
- Autoimmune Diseases Research Center, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran
| |
Collapse
|
2
|
Moreira DA, Santos SD, Leiro V, Pêgo AP. Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer's Disease. Pharmaceutics 2023; 15:pharmaceutics15041054. [PMID: 37111540 PMCID: PMC10140951 DOI: 10.3390/pharmaceutics15041054] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 03/15/2023] [Accepted: 03/18/2023] [Indexed: 04/29/2023] Open
Abstract
Alzheimer's disease (AD) is the most prevalent form of dementia. It affects more than 30 million people worldwide and costs over US$ 1.3 trillion annually. AD is characterized by the brain accumulation of amyloid β peptide in fibrillar structures and the accumulation of hyperphosphorylated tau aggregates in neurons, both leading to toxicity and neuronal death. At present, there are only seven drugs approved for the treatment of AD, of which only two can slow down cognitive decline. Moreover, their use is only recommended for the early stages of AD, meaning that the major portion of AD patients still have no disease-modifying treatment options. Therefore, there is an urgent need to develop efficient therapies for AD. In this context, nanobiomaterials, and dendrimers in particular, offer the possibility of developing multifunctional and multitargeted therapies. Due to their intrinsic characteristics, dendrimers are first-in-class macromolecules for drug delivery. They have a globular, well-defined, and hyperbranched structure, controllable nanosize and multivalency, which allows them to act as efficient and versatile nanocarriers of different therapeutic molecules. In addition, different types of dendrimers display antioxidant, anti-inflammatory, anti-bacterial, anti-viral, anti-prion, and most importantly for the AD field, anti-amyloidogenic properties. Therefore, dendrimers can not only be excellent nanocarriers, but also be used as drugs per se. Here, the outstanding properties of dendrimers and derivatives that make them excellent AD nanotherapeutics are reviewed and critically discussed. The biological properties of several dendritic structures (dendrimers, derivatives, and dendrimer-like polymers) that enable them to be used as drugs for AD treatment will be pointed out and the chemical and structural characteristics behind those properties will be analysed. The reported use of these nanomaterials as nanocarriers in AD preclinical research is also presented. Finally, future perspectives and challenges that need to be overcome to make their use in the clinic a reality are discussed.
Collapse
Affiliation(s)
- Débora A Moreira
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
- INEB-Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
- FEUP-Faculdade de Engenharia, Universidade do Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
| | - Sofia D Santos
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
- INEB-Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
| | - Victoria Leiro
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
- INEB-Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
| | - Ana P Pêgo
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
- INEB-Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal
- ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua Jorge de Viterbo Ferreira 228, 4050-313 Porto, Portugal
| |
Collapse
|
3
|
Pérez-carrión MD, Posadas I. Dendrimers in Neurodegenerative Diseases. Processes (Basel) 2023; 11:319. [DOI: 10.3390/pr11020319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Neurodegenerative diseases (NDs), such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Multiple Sclerosis (MS) and amyotrophic lateral sclerosis (ALS), are characterized by progressive loss of structure or function of neurons. Current therapies for NDs are only symptomatic and long-term ineffective. This challenge has promoted the development of new therapies against relevant targets in these pathologies. In this review, we will focus on the most promising therapeutic approaches based on dendrimers (DDs) specially designed for the treatment and diagnosis of NDs. DDs are well-defined polymeric structures that provide a multifunctional platform for developing different nanosystems for a myriad of applications. DDs have been proposed as interesting drug delivery systems with the ability to cross the blood–brain barrier (BBB) and increase the bioavailability of classical drugs in the brain, as well as genetic material, by reducing the synthesis of specific targets, as β-amyloid peptide. Moreover, DDs have been shown to be promising anti-amyloidogenic systems against amyloid-β peptide (Aβ) and Tau aggregation, powerful agents for blocking α-synuclein (α-syn) fibrillation, exhibit anti-inflammatory properties, promote cellular uptake to certain cell types, and are potential tools for ND diagnosis. In summary, DDs have emerged as promising alternatives to current ND therapies since they may limit the extent of damage and provide neuroprotection to the affected tissues.
Collapse
|
4
|
Bhosale A, Paul G, Mazahir F, Yadav A. Theoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases. OpenNano 2023. [DOI: 10.1016/j.onano.2022.100111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
5
|
Rahman MM, Islam MR, Akash S, Harun-Or-Rashid M, Ray TK, Rahaman MS, Islam M, Anika F, Hosain MK, Aovi FI, Hemeg HA, Rauf A, Wilairatana P. Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance. Biomed Pharmacother 2022; 153:113305. [PMID: 35717779 DOI: 10.1016/j.biopha.2022.113305] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 06/06/2022] [Accepted: 06/13/2022] [Indexed: 11/28/2022] Open
Abstract
Nanoscale engineering is one of the innovative approaches to heal multitudes of ailments, such as varieties of malignancies, neurological problems, and infectious illnesses. Therapeutics for neurodegenerative diseases (NDs) may be modified in aspect because of their ability to stimulate physiological response while limiting negative consequences by interfacing and activating possible targets. Nanomaterials have been extensively studied and employed for cancerous therapeutic strategies since nanomaterials potentially play a significant role in medical transportation. When compared to conventional drug delivery, nanocarriers drug delivery offers various benefits, such as excellent reliability, bioactivity, improved penetration and retention impact, as well as precise targeting and administering. Upregulation of drug efflux transporters, dysfunctional apoptotic mechanisms, and a hypoxic atmosphere are all elements that lead to cancer treatment sensitivity in humans. It has been possible to target these pathways using nanoparticles and increase the effectiveness of multidrug resistance treatments. As innovative strategies of tumor chemoresistance are uncovered, nanomaterials are being developed to target specific pathways of tumor resilience. Scientists have recently begun investigating the function of nanoparticles in immunotherapy, a field that is becoming increasingly useful in the care of malignancies. Nanoscale therapeutics have been explored in this scientific literature and represent the most current approaches to neurodegenerative illnesses and cancer therapy. In addition, current findings and various biomedical nanomaterials' future promise for tissue regeneration, prospective medication design, and the synthesis of novel delivery approaches have been emphasized.
Collapse
Affiliation(s)
- Md Mominur Rahman
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Md Rezaul Islam
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Shopnil Akash
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Md Harun-Or-Rashid
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Tanmay Kumar Ray
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Md Saidur Rahaman
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Mahfuzul Islam
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Fazilatunnesa Anika
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Md Kawser Hosain
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Farjana Islam Aovi
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, 1207 Dhaka, Bangladesh
| | - Hassan A Hemeg
- Department of Medical Laboratory Technology, College of Applied Medical Sciences, Taibah University, P.O. Box 344, Al-Madinah Al-Monawra 41411, Saudi Arabia
| | - Abdur Rauf
- Department of Chemistry, University of Swabi, Anbar, Khyber Pakhtunkhwa, Pakistan.
| | - Polrat Wilairatana
- Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
| |
Collapse
|
6
|
Ferrer-Lorente R, Lozano-Cruz T, Fernández-Carasa I, Miłowska K, de la Mata FJ, Bryszewska M, Consiglio A, Ortega P, Gómez R, Raya A. Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons. Biomacromolecules 2021; 22:4582-4591. [PMID: 34613701 PMCID: PMC8906628 DOI: 10.1021/acs.biomac.1c00884] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
![]()
Accumulation
of misfolded α-synuclein (α-syn) is a
hallmark of Parkinson’s disease (PD) thought to play important
roles in the pathophysiology of the disease. Dendritic systems, able
to modulate the folding of proteins, have emerged as promising new
therapeutic strategies for PD treatment. Dendrimers have been shown
to be effective at inhibiting α-syn aggregation in cell-free
systems and in cell lines. Here, we set out to investigate the effects
of dendrimers on endogenous α-syn accumulation in disease-relevant
cell types from PD patients. For this purpose, we chose cationic carbosilane
dendrimers of bow-tie topology based on their performance at inhibiting
α-syn aggregation in vitro. Dopamine neurons
were differentiated from induced pluripotent stem cell (iPSC) lines
generated from PD patients carrying the LRRK2G2019S mutation, which reportedly display
abnormal accumulation of α-syn, and from healthy individuals
as controls. Treatment of PD dopamine neurons with non-cytotoxic concentrations
of dendrimers was effective at preventing abnormal accumulation and
aggregation of α-syn. Our results in a genuinely human experimental
model of PD highlight the therapeutic potential of dendritic systems
and open the way to developing safe and efficient therapies for delaying
or even halting PD progression.
Collapse
Affiliation(s)
- Raquel Ferrer-Lorente
- Regenerative Medicine Program, and Program for Clinical Translation of Regenerative Medicine in Catalonia─P-CMR[C], L'Hospitalet de Llobregat (Barcelona), Institut d'Investigació Biomèdica de Bellvitge─IDIBELL, Barcelona 08907, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain
| | - Tania Lozano-Cruz
- University of Alcalá, Department of Organic Chemistry and Inorganic Chemistry and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid 28805, Spain
| | - Irene Fernández-Carasa
- Department of Pathology and Experimental Therapeutics, Hospitalet de Llobregat (Barcelona), Universitat de Barcelona and Institut d'Investigació Biomèdica de Bellvitge─IDIBELL, Barcelona 08907, Spain
| | - Katarzyna Miłowska
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, Lodz 90-236, Poland
| | - Francisco Javier de la Mata
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain.,University of Alcalá, Department of Organic Chemistry and Inorganic Chemistry and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid 28805, Spain
| | - Maria Bryszewska
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, Lodz 90-236, Poland
| | - Antonella Consiglio
- Department of Pathology and Experimental Therapeutics, Hospitalet de Llobregat (Barcelona), Universitat de Barcelona and Institut d'Investigació Biomèdica de Bellvitge─IDIBELL, Barcelona 08907, Spain.,Department of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy
| | - Paula Ortega
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain.,University of Alcalá, Department of Organic Chemistry and Inorganic Chemistry and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid 28805, Spain
| | - Rafael Gómez
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain.,University of Alcalá, Department of Organic Chemistry and Inorganic Chemistry and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid 28805, Spain
| | - Angel Raya
- Regenerative Medicine Program, and Program for Clinical Translation of Regenerative Medicine in Catalonia─P-CMR[C], L'Hospitalet de Llobregat (Barcelona), Institut d'Investigació Biomèdica de Bellvitge─IDIBELL, Barcelona 08907, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08907, Spain
| |
Collapse
|
7
|
Singh A, Maharana SK, Shukla R, Kesharwani P. Nanotherapeutics approaches for targeting alpha synuclien protein in the management of Parkinson disease. Process Biochem 2021. [DOI: 10.1016/j.procbio.2021.08.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
8
|
D’Onofrio M, Munari F, Assfalg M. Alpha-Synuclein-Nanoparticle Interactions: Understanding, Controlling and Exploiting Conformational Plasticity. Molecules 2020; 25:E5625. [PMID: 33260436 PMCID: PMC7731430 DOI: 10.3390/molecules25235625] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 11/25/2020] [Accepted: 11/27/2020] [Indexed: 12/29/2022] Open
Abstract
Alpha-synuclein (αS) is an extensively studied protein due to its involvement in a group of neurodegenerative disorders, including Parkinson's disease, and its documented ability to undergo aberrant self-aggregation resulting in the formation of amyloid-like fibrils. In dilute solution, the protein is intrinsically disordered but can adopt multiple alternative conformations under given conditions, such as upon adsorption to nanoscale surfaces. The study of αS-nanoparticle interactions allows us to better understand the behavior of the protein and provides the basis for developing systems capable of mitigating the formation of toxic aggregates as well as for designing hybrid nanomaterials with novel functionalities for applications in various research areas. In this review, we summarize current progress on αS-nanoparticle interactions with an emphasis on the conformational plasticity of the biomolecule.
Collapse
Affiliation(s)
| | | | - Michael Assfalg
- Department of Biotechnology, University of Verona, 37134 Verona, Italy; (M.D.); (F.M.)
| |
Collapse
|
9
|
Baskin J, Jeon JE, Lewis SJG. Nanoparticles for drug delivery in Parkinson's disease. J Neurol 2020; 268:1981-1994. [PMID: 33141248 DOI: 10.1007/s00415-020-10291-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/20/2020] [Accepted: 10/22/2020] [Indexed: 12/22/2022]
Abstract
Although effective symptomatic treatments for Parkinson's disease (PD) have been available for some time, efficient and well-controlled drug delivery to the brain has proven to be challenging. The emergence of nanotechnology has created new opportunities not only for improving the pharmacokinetics of conventional therapies but also for developing novel treatment approaches and disease modifying therapies. Several exciting strategies including drug carrier nanoparticles targeting specific intracellular pathways and structural reconformation of tangled proteins as well as introducing reprogramming genes have already shown promise and are likely to deliver more tailored approaches to the treatment of PD in the future. This paper reviews the role of nanoparticles in PD including a discussion of both their composition and functional capacity as well as their potential to deliver better therapeutic agents.
Collapse
Affiliation(s)
- Jonathan Baskin
- Parkinson's Disease Research Clinic, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.
| | - June Evelyn Jeon
- Parkinson's Disease Research Clinic, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia
| | - Simon J G Lewis
- Parkinson's Disease Research Clinic, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia
| |
Collapse
|
10
|
Muda MS, Kamari A, Bakar SA, Yusoff SNM, Fatimah I, Phillip E, Din SM. Chitosan-graphene oxide nanocomposites as water-solubilising agents for rotenone pesticide. J Mol Liq 2020; 318:114066. [DOI: 10.1016/j.molliq.2020.114066] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
11
|
Rabiee N, Ahmadvand S, Ahmadi S, Fatahi Y, Dinarvand R, Bagherzadeh M, Rabiee M, Tahriri M, Tayebi L, Hamblin MR. Carbosilane dendrimers: Drug and gene delivery applications. J Drug Deliv Sci Technol 2020; 59:101879. [DOI: 10.1016/j.jddst.2020.101879] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
12
|
|
13
|
Michlewska S, Ionov M, Szwed A, Rogalska A, Sanz del Olmo N, Ortega P, Denel M, Jacenik D, Shcharbin D, de la Mata FJ, Bryszewska M. Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells. Int J Mol Sci 2020; 21:ijms21114119. [PMID: 32526993 PMCID: PMC7312499 DOI: 10.3390/ijms21114119] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 05/27/2020] [Accepted: 06/02/2020] [Indexed: 02/08/2023] Open
Abstract
Ruthenium atoms located in the surfaces of carbosilane dendrimers markedly increase their anti-tumor properties. Carbosilane dendrimers have been widely studied as carriers of drugs and genes owing to such characteristic features as monodispersity, stability, and multivalence. The presence of ruthenium in the dendrimer structure enhances their successful use in anti-cancer therapy. In this paper, the activity of dendrimers of generation 1 and 2 against 1301 cells was evaluated using Transmission Electron Microscopy, comet assay and Real Time PCR techniques. Additionally, the level of reactive oxygen species (ROS) and changes of mitochondrial potential values were assessed. The results of the present study show that ruthenium dendrimers significantly decrease the viability of leukemia cells (1301) but show low toxicity to non-cancer cells (peripheral blood mononuclear cells-PBMCs). The in vitro test results indicate that the dendrimers injure the 1301 leukemia cells via the apoptosis pathway.
Collapse
Affiliation(s)
- Sylwia Michlewska
- Laboratory of Microscopic Imaging & Specialized Biological Techniques, Faculty of Biology & Environmental Protection, University of Lodz, 90-237 Lodz, Poland
- Department of General Biophysics, Faculty of Biology & Environmental Protection, University of Lodz, 90-236 Lodz, Poland; (A.S.); (M.B.)
- Correspondence: (S.M.); (M.I.)
| | - Maksim Ionov
- Department of General Biophysics, Faculty of Biology & Environmental Protection, University of Lodz, 90-236 Lodz, Poland; (A.S.); (M.B.)
- Correspondence: (S.M.); (M.I.)
| | - Aleksandra Szwed
- Department of General Biophysics, Faculty of Biology & Environmental Protection, University of Lodz, 90-236 Lodz, Poland; (A.S.); (M.B.)
| | - Aneta Rogalska
- Department of Medical Biophysics, Faculty of Biology & Protection, University of Lodz, 90-236 Lodz, Poland; (A.R.); (M.D.)
| | - Natalia Sanz del Olmo
- Networking Research Center on Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), 28029 Madrid, Spain; (N.S.d.O.); (P.O.); (F.J.d.l.M.)
- Department of Organic Chemistry and Inorganic Chemistry, Research Institute of Chemistry “Andrés M. del Rio (IQAR)”, Institute “Ramón y Cajal” for Health Research (IRYCIS), University of Alcalá, 28805 Madrid, Spain
| | - Paula Ortega
- Networking Research Center on Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), 28029 Madrid, Spain; (N.S.d.O.); (P.O.); (F.J.d.l.M.)
- Department of Organic Chemistry and Inorganic Chemistry, Research Institute of Chemistry “Andrés M. del Rio (IQAR)”, Institute “Ramón y Cajal” for Health Research (IRYCIS), University of Alcalá, 28805 Madrid, Spain
| | - Marta Denel
- Department of Medical Biophysics, Faculty of Biology & Protection, University of Lodz, 90-236 Lodz, Poland; (A.R.); (M.D.)
| | - Damian Jacenik
- Department of Cytobiochemistry, Faculty of Biology & Protection, University of Lodz, 90-236 Lodz, Poland;
| | - Dzmitry Shcharbin
- Institute of Biophysics & Cell Engineering of NASB, 220072 Minsk, Belarus;
| | - Francisco Javier de la Mata
- Networking Research Center on Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), 28029 Madrid, Spain; (N.S.d.O.); (P.O.); (F.J.d.l.M.)
- Department of Organic Chemistry and Inorganic Chemistry, Research Institute of Chemistry “Andrés M. del Rio (IQAR)”, Institute “Ramón y Cajal” for Health Research (IRYCIS), University of Alcalá, 28805 Madrid, Spain
| | - Maria Bryszewska
- Department of General Biophysics, Faculty of Biology & Environmental Protection, University of Lodz, 90-236 Lodz, Poland; (A.S.); (M.B.)
| |
Collapse
|
14
|
Lozano-Cruz T, Alcarraz-Vizán G, de la Mata FJ, de Pablo S, Ortega P, Duarte Y, Bravo-Moraga F, González-Nilo FD, Novials A, Gómez R. Cationic Carbosilane Dendritic Systems as Promising Anti-Amyloid Agents in Type 2 Diabetes. Chemistry 2020; 26:7609-7621. [PMID: 32259327 DOI: 10.1002/chem.202000091] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 03/31/2020] [Indexed: 01/10/2023]
Abstract
The most common denominator of many of the neurodegenerative diseases is badly folded protein accumulation, which results in the formation of insoluble protein deposits located in different parts of the organism, causing cell death and tissue degeneration. Dendritic systems have turned out to be a promising new therapeutic approach for the treatment of these diseases due to their ability to modulate the folding of these proteins. With this perspective, and focused on type 2 diabetes (T2D), characterized by the presence of deposits containing the amyloidogenic islet amyloid polypeptide (IAPP), we demonstrate how different topologies of cationic carbosilane dendrimers inhibit the formation of insoluble protein deposits in pancreatic islets isolated from transgenic Tg-hIAPP mice. Also, the results obtained by the modification of dendritic carbosilane wedges with the chemical chaperone 4-phenylbutyric acid (4-PBA) at the focal point confirmed their potential as anti-amyloid agents with a concentration efficiency in their therapeutic action five orders of magnitude lower than that observed for free 4-PBA. Computational studies, which determined the main interaction between IAPP and dendrimers at the atomic level, support the experimental work.
Collapse
Affiliation(s)
- Tania Lozano-Cruz
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. Del Río" (IQAR), University of Alcalá, 28805, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 028029, Madrid, Spain.,Ramón y Cajal Health Research Institute (IRYCIS), IRYCIS, Colmenar Viejo Road, Km 9, 100, 28034, Madrid, Spain
| | - Gema Alcarraz-Vizán
- Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, 08028, Barcelona, Spain.,Spanish Biomedical Research Centre Diabetes and, Associated Metabolic Disorders (CIBERDEM), 08028, Barcelona, Spain
| | - F Javier de la Mata
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. Del Río" (IQAR), University of Alcalá, 28805, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 028029, Madrid, Spain.,Ramón y Cajal Health Research Institute (IRYCIS), IRYCIS, Colmenar Viejo Road, Km 9, 100, 28034, Madrid, Spain
| | - Sara de Pablo
- Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, 08028, Barcelona, Spain
| | - Paula Ortega
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. Del Río" (IQAR), University of Alcalá, 28805, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 028029, Madrid, Spain.,Ramón y Cajal Health Research Institute (IRYCIS), IRYCIS, Colmenar Viejo Road, Km 9, 100, 28034, Madrid, Spain
| | - Yorley Duarte
- Center for Bioinformatics and Integrative Biology (CBIB), Facultad de Ciencias Biológicas, Universidad Andres Bello, 8370146, Santiago, Chile
| | - Felipe Bravo-Moraga
- Center for Bioinformatics and Integrative Biology (CBIB), Facultad de Ciencias Biológicas, Universidad Andres Bello, 8370146, Santiago, Chile
| | - Fernando D González-Nilo
- Center for Bioinformatics and Integrative Biology (CBIB), Facultad de Ciencias Biológicas, Universidad Andres Bello, 8370146, Santiago, Chile.,Interdisciplinary Center for Neuroscience of Valparaíso, Faculty of Science, University of Valparaíso, 2340000, Valparaíso, Chile
| | - Anna Novials
- Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, 08028, Barcelona, Spain.,Spanish Biomedical Research Centre Diabetes and, Associated Metabolic Disorders (CIBERDEM), 08028, Barcelona, Spain
| | - Rafael Gómez
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. Del Río" (IQAR), University of Alcalá, 28805, Madrid, Spain.,Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 028029, Madrid, Spain.,Ramón y Cajal Health Research Institute (IRYCIS), IRYCIS, Colmenar Viejo Road, Km 9, 100, 28034, Madrid, Spain
| |
Collapse
|
15
|
Sanz Del Olmo N, Bajo AM, Ionov M, García-Gallego S, Bryszewska M, Gómez R, Ortega P, de la Mata FJ. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer. Eur J Med Chem 2020; 199:112414. [PMID: 32438200 DOI: 10.1016/j.ejmech.2020.112414] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 04/16/2020] [Accepted: 04/28/2020] [Indexed: 12/19/2022]
Abstract
In searching for efficient and selective antitumour drugs, a new family of carbosilane metallodendrimers functionalized with [Ru(η5-C5H5)(PTA)Cl] (PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1] decane) is reported. Experiments of the biophysical characterization showed an ability to interact with biological membranes, as well as with proteins (e.g. human serum albumin) without affecting their usual biological activity. These metallodendrimers possessed potent and selective anticancer activity in vitro in a panel of tumour cell lines. Importantly, the first generation metallodendrimer, bearing 4 Ru(II) complexes, was remarkably active towards resistant prostate cancer cells, inhibiting both cell proliferation and metastasis to bone tissues. Such promising antitumour activity can be further improved when given with docetaxel, with in vitro cytotoxicity being in the nanomolar range. Furthermore, its intravenous administration to an advanced prostate cancer mice model inhibited tumour growth up to 25% and 45% when given 10 mg/kg/week and 7.5 mg/kg/4-5 days, respectively.
Collapse
Affiliation(s)
- Natalia Sanz Del Olmo
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain
| | - Ana M Bajo
- Department of Biology of Systems, Biochemistry and Molecular Biology Unit, University of Alcalá, Madrid, Spain
| | - Maksim Ionov
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236, Lodz, Poland
| | - Sandra García-Gallego
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain
| | - Maria Bryszewska
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236, Lodz, Poland
| | - Rafael Gómez
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain and Institute "Ramón y Cajal" for Health Research (IRYCIS), Spain
| | - Paula Ortega
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain and Institute "Ramón y Cajal" for Health Research (IRYCIS), Spain.
| | - F Javier de la Mata
- Department of Organic and Inorganic Chemistry, Research Institute in Chemistry "Andrés M. del Río" (IQAR), University of Alcalá, Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain and Institute "Ramón y Cajal" for Health Research (IRYCIS), Spain.
| |
Collapse
|
16
|
Szwed A, Miłowska K, Michlewska S, Moreno S, Shcharbin D, Gomez-Ramirez R, de la Mata FJ, Majoral JP, Bryszewska M, Gabryelak T. Generation Dependent Effects and Entrance to Mitochondria of Hybrid Dendrimers on Normal and Cancer Neuronal Cells In Vitro. Biomolecules 2020; 10:E427. [PMID: 32182909 DOI: 10.3390/biom10030427] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 02/23/2020] [Accepted: 02/24/2020] [Indexed: 11/16/2022] Open
Abstract
Dendrimers as drug carriers can be utilized for drugs and siRNA delivery in central nervous system (CNS) disorders, including various types of cancers, such as neuroblastomas and gliomas. They have also been considered as drugs per se, for example as anti-Alzheimer's disease (AD), anti-cancer, anti-prion or anti-inflammatory agents. Since the influence of carbosilane-viologen-phosphorus dendrimers (SMT1 and SMT2) on the basic cellular processes of nerve cells had not been investigated, we examined the impact of two generations of these hybrid macromolecules on two murine cell lines-cancer cell line N2a (mouse neuroblastoma) and normal immortalized cell line mHippoE-18 (embryonic mouse hippocampal cell line). We examined alterations in cellular responses including the activity of mitochondrial dehydrogenases, the generation of reactive oxygen species (ROS), changes in mitochondrial membrane potential, and morphological modifications and fractions of apoptotic and dead cells. Our results show that both dendrimers at low concentrations affected the cancer cell line more than the normal one. Also, generation-dependent effects were found: the highest generation induced greater cytotoxic effects and morphological modifications. The most promising is that the changes in mitochondrial membrane potential and transmission electron microscopy (TEM) images indicate that dendrimer SMT1 can reach mitochondria. Thus, SMT1 and SMT2 seem to have potential as nanocarriers to mitochondria or anti-cancer drugs per se in CNS disorders.
Collapse
|
17
|
Rajpoot K. Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines. Curr Drug Targets 2020; 21:819-836. [PMID: 31906836 DOI: 10.2174/1389450121666200106105633] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 12/18/2019] [Accepted: 12/18/2019] [Indexed: 12/13/2022]
Abstract
Traditional drug delivery approaches remained ineffective in offering better treatment to various neurodegenerative disorders (NDs). In this context, diverse types of nanocarriers have shown their great potential to cross the blood-brain barrier (BBB) and have emerged as a prominent carrier system in drug delivery. Moreover, nanotechnology-based methods usually involve numerous nanosized carrier platforms, which potentiate the effect of the therapeutic agents in the therapy of NDs especially in diagnosis and drug delivery with negligible side effects. In addition, nanotechnology-based techniques have offered several strategies to cross BBB to intensify the bioavailability of drug moieties in the brain. In the last few years, diverse kinds of nanoparticles (NPs) have been developed by incorporating various biocompatible components (e.g., polysaccharide-based NPs, polymeric NPs, selenium NPs, AuNPs, protein-based NPs, gadolinium NPs, etc.), that showed great therapeutic benefits against NDs. Eventually, this review provides deep insights to explore recent applications of some innovative nanocarriers enclosing active molecules for the efficient treatment of NDs.
Collapse
Affiliation(s)
- Kuldeep Rajpoot
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, 495 009, Chhattisgarh, India
| |
Collapse
|
18
|
Pedziwiatr-Werbicka E, Milowska K, Dzmitruk V, Ionov M, Shcharbin D, Bryszewska M. Dendrimers and hyperbranched structures for biomedical applications. Eur Polym J 2019. [DOI: 10.1016/j.eurpolymj.2019.07.013] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
19
|
Michlewska S, Ionov M, Maroto-Díaz M, Szwed A, Ihnatsyeu-Kachan A, Abashkin V, Dzmitruk V, Rogalska A, Denel M, Gapinska M, Shcharbin D, Gomez Ramirez R, de la Mata FJ, Bryszewska M. Ruthenium dendrimers against acute promyelocytic leukemia: in vitro studies on HL-60 cells. Future Med Chem 2019; 11:1741-56. [PMID: 31287722 DOI: 10.4155/fmc-2018-0274] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Coordination of ruthenium arene fragments on carbosilane dendrimers' surface greatly increases their antitumor properties. Newly synthetized ruthenium dendrimers are water-soluble, monodisperse and stable. Since carbosilane dendrimers are good carriers of drugs and genes, the presence of ruthenium in their structure makes them promising candidates for new drug delivery systems with improved antitumor potential. Carbosilane ruthenium dendrimers are more toxic to cancer cells than normal cells. Results of several in vitro studies applied here indicate that carbosilane ruthenium dendrimers induce apoptosis in promyelocytic leukemia HL-60 cells.
Collapse
|
20
|
|
21
|
Oliveri V. Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation. Eur J Med Chem 2019; 167:10-36. [PMID: 30743095 DOI: 10.1016/j.ejmech.2019.01.045] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2018] [Revised: 01/21/2019] [Accepted: 01/21/2019] [Indexed: 12/17/2022]
Abstract
A host of human diseases, including Parkinson's disease and Dementia with Lewy bodies, are suspected to be directly linked to protein aggregation. Amyloid protein aggregates and oligomeric intermediates of α-synuclein are observed in synucleinopathies and considered to be mediators of cellular toxicity. Hence, α-synuclein has seen as one of the leading and most compelling targets and is receiving a great deal of attention from researchers. Nevertheless, there is no neuroprotective approach directed toward Parkinson's disease or other synucleinopathies so far. In this review, we summarize the available data concerning inhibitors of α-synuclein aggregation and their advancing towards clinical use. The compounds are grouped according to their chemical structures, providing respective insights into their mechanism of action, pharmacology, and pharmacokinetics. Overall, shared structure-activity elements are emerging, as well as specific binding modes related to the ability of the modulators to establish hydrophobic and hydrogen bonds interactions with the protein. Some molecules with encouraging in vivo data support the possibility of translation to the clinic.
Collapse
Affiliation(s)
- Valentina Oliveri
- Dipartimento di Scienze Chimiche, Università degli Studi di Catania, viale A. Doria 6, 95125, Catania, Italy.
| |
Collapse
|
22
|
Lozano-Cruz T, Gómez R, de la Mata FJ, Ortega P. New bow-tie cationic carbosilane dendritic system with a curcumin core as an anti-breast cancer agent. NEW J CHEM 2018. [DOI: 10.1039/c8nj01713a] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A water soluble “bow-tie” cationic carbosilane dendrimer with curcumin in the core displays antioxidant and antitumoral activities against breast cancer cells.
Collapse
Affiliation(s)
- Tania Lozano-Cruz
- Departamento de Química Orgánica y Química Inorgánica. Instituto de Investigación Química “Andrés M. del Río” (IQAR)
- Universidad de Alcalá
- Campus Universitario
- E-28871 Alcalá de Henares
- Spain
| | - Rafael Gómez
- Departamento de Química Orgánica y Química Inorgánica. Instituto de Investigación Química “Andrés M. del Río” (IQAR)
- Universidad de Alcalá
- Campus Universitario
- E-28871 Alcalá de Henares
- Spain
| | - F. Javier de la Mata
- Departamento de Química Orgánica y Química Inorgánica. Instituto de Investigación Química “Andrés M. del Río” (IQAR)
- Universidad de Alcalá
- Campus Universitario
- E-28871 Alcalá de Henares
- Spain
| | - Paula Ortega
- Departamento de Química Orgánica y Química Inorgánica. Instituto de Investigación Química “Andrés M. del Río” (IQAR)
- Universidad de Alcalá
- Campus Universitario
- E-28871 Alcalá de Henares
- Spain
| |
Collapse
|
23
|
Sanz Del Olmo N, Maroto-Díaz M, Gómez R, Ortega P, Cangiotti M, Ottaviani MF, de la Mata FJ. Carbosilane metallodendrimers based on copper (II) complexes: Synthesis, EPR characterization and anticancer activity. J Inorg Biochem 2017; 177:211-218. [PMID: 29031179 DOI: 10.1016/j.jinorgbio.2017.09.023] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Revised: 09/20/2017] [Accepted: 09/24/2017] [Indexed: 01/25/2023]
Abstract
A series of new organometallic carbosilane dendrimers functionalized with Copper(II) complex on the surface were synthesized and characterized as potential anticancer agents. These metallodendrimers were synthesized through the reaction of dendritic ligands containing N,N- and N,O- donor atoms able to act as chelating agents with CuCl2 as metallic ion precursor. The structural characterization of these complexes was addressed through the use of different analytical and spectroscopical techniques. Particularly, an electron paramagnetic resonance study was performed to corroborate the coordination properties of these dendritic ligands. A preliminary study was carried out to establish the cytotoxicity of the new synthesized compounds in human prostate (PC3) and human cervical (HeLa) cancer cell lines in order to evaluate their potential as anticancer agents and compare their activity with other copper or analogous ruthenium metallodendrimers.
Collapse
Affiliation(s)
- Natalia Sanz Del Olmo
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871, Alcalá de Henares, Spain
| | - Marta Maroto-Díaz
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871, Alcalá de Henares, Spain
| | - Rafael Gómez
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871, Alcalá de Henares, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.
| | - Paula Ortega
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871, Alcalá de Henares, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - Michela Cangiotti
- Department of Earth, Life and Environment Sciences, University of Urbino, Urbino, 61029, Italy
| | - M Francesca Ottaviani
- Department of Earth, Life and Environment Sciences, University of Urbino, Urbino, 61029, Italy.
| | - F Javier de la Mata
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871, Alcalá de Henares, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.
| |
Collapse
|
24
|
Shcharbin D, Shcharbina N, Dzmitruk V, Pedziwiatr-Werbicka E, Ionov M, Mignani S, de la Mata FJ, Gómez R, Muñoz-Fernández MA, Majoral JP, Bryszewska M. Dendrimer-protein interactions versus dendrimer-based nanomedicine. Colloids Surf B Biointerfaces 2017; 152:414-422. [PMID: 28167455 DOI: 10.1016/j.colsurfb.2017.01.041] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Revised: 01/22/2017] [Accepted: 01/23/2017] [Indexed: 12/12/2022]
Abstract
Dendrimers are hyperbranched polymers belonging to the huge class of nanomedical devices. Their wide application in biology and medicine requires understanding of the fundamental mechanisms of their interactions with biological systems. Summarizing, electrostatic force plays the predominant role in dendrimer-protein interactions, especially with charged dendrimers. Other kinds of interactions have been proven, such as H-bonding, van der Waals forces, and even hydrophobic interactions. These interactions depend on the characteristics of both participants: flexibility and surface charge of a dendrimer, rigidity of protein structure and the localization of charged amino acids at its surface. pH and ionic strength of solutions can significantly modulate interactions. Ligands and cofactors attached to a protein can also change dendrimer-protein interactions. Binding of dendrimers to a protein can change its secondary structure, conformation, intramolecular mobility and functional activity. However, this strongly depends on rigidity versus flexibility of a protein's structure. In addition, the potential applications of dendrimers to nanomedicine are reviwed related to dendrimer-protein interactions.
Collapse
Affiliation(s)
- Dzmitry Shcharbin
- Institute of Biophysics and Cell Engineering of NASB, Minsk, Belarus.
| | | | - Volha Dzmitruk
- Institute of Biophysics and Cell Engineering of NASB, Minsk, Belarus
| | - Elzbieta Pedziwiatr-Werbicka
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Maksim Ionov
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Serge Mignani
- Université Paris Descartes, Laboratoire de Chimie et de Biochimie pharmacologiques et toxicologique, Paris, France
| | - F Javier de la Mata
- Departamento Química Orgánica y Química Inorgánica, Universidad de Alcalá, Alcalá de Henares, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain
| | - Rafael Gómez
- Departamento Química Orgánica y Química Inorgánica, Universidad de Alcalá, Alcalá de Henares, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain
| | - Maria Angeles Muñoz-Fernández
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain; Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Spanish HIV-HGM BioBank, Madrid, Spain
| | - Jean-Pierre Majoral
- Laboratoire de Chimie de Coordination, CNRS, Toulouse, France; Université de Toulouse, Toulouse, France
| | - Maria Bryszewska
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| |
Collapse
|
25
|
Mignani S, Bryszewska M, Zablocka M, Klajnert-Maculewicz B, Cladera J, Shcharbin D, Majoral JP. Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches. Prog Polym Sci 2017. [DOI: 10.1016/j.progpolymsci.2016.09.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
26
|
Szwed A, Milowska K, Ionov M, Shcharbin D, Moreno S, Gomez-Ramirez R, de la Mata FJ, Majoral JP, Bryszewska M, Gabryelak T. Interaction between dendrimers and regulatory proteins. Comparison of effects of carbosilane and carbosilane–viologen–phosphorus dendrimers. RSC Adv 2016. [DOI: 10.1039/c6ra16558c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
For nanoparticles to be used successfully in biomedical application, their interactions with biological fluids need to be investigated, in which they will react with proteins and other macromolecules.
Collapse
|
27
|
Mencia G, del Olmo NS, Muñoz-Moreno L, Maroto-Diaz M, Gomez R, Ortega P, José Carmena M, Javier de la Mata F. Polyphenolic carbosilane dendrimers as anticancer agents against prostate cancer. NEW J CHEM 2016. [DOI: 10.1039/c6nj02545e] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Polyphenolic carbosilane dendrimers improved the antioxidant and anticancer properties of free vanillin.
Collapse
Affiliation(s)
- Gabriel Mencia
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá
- Campus Universitario
- Edificio de Farmacia
- E-28871 Alcalá de Henares
- Spain
| | - Natalia Sanz del Olmo
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá
- Campus Universitario
- Edificio de Farmacia
- E-28871 Alcalá de Henares
- Spain
| | - Laura Muñoz-Moreno
- Departamento de Biología de Sistemas, Universidad de Alcalá
- Campus Universitario
- E-28871 Alcalá de Henares
- Spain
| | - Marta Maroto-Diaz
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá
- Campus Universitario
- Edificio de Farmacia
- E-28871 Alcalá de Henares
- Spain
| | - Rafael Gomez
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá
- Campus Universitario
- Edificio de Farmacia
- E-28871 Alcalá de Henares
- Spain
| | - Paula Ortega
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá
- Campus Universitario
- Edificio de Farmacia
- E-28871 Alcalá de Henares
- Spain
| | - Ma José Carmena
- Departamento de Biología de Sistemas, Universidad de Alcalá
- Campus Universitario
- E-28871 Alcalá de Henares
- Spain
| | - F. Javier de la Mata
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá
- Campus Universitario
- Edificio de Farmacia
- E-28871 Alcalá de Henares
- Spain
| |
Collapse
|